BRCA2 and breast cancer: The prevalence of pathogenic BRCA2 mutations in breast cancer cases is, however, less than for BRCA1 in most of Western Europe and North America, which may be why reports on the outcome of early diagnosis with MRI in carriers of pathogenic BRCA2 mutations are even sparser.